immatics Receives EUR22 Million Final Tranche of Series D Fundraising
TUEBINGEN, Germany, July 16, 2014 /PRNewswire/ –
Funds will be used to complete phase 3 study with IMA901 and to invest in
the expansion of immatics’ Human Immunopeptidome Program to identify the most relevant
targets for cancer immunotherapies
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company leading the
development of advanced immunotherapies that are active against cancer, today announces
that it has received EUR22m to complete a Series D financing round. The Company received
EUR12m in October 2013 as an initial tranche of the total EUR34m funding round.
The Series D funding was supported by existing investors including dievini Hopp
Biotech holding, Wellington Partners, and AT Impf GmbH and others.
immatics will use this funding to complete the current phase 3 trial with its lead
cancer vaccine IMA901 in patients with renal cell carcinoma (RCC). The trial is evaluating
overall survival with IMA901 in combination with sunitinib (Sutent(R), Pfizer), a current
standard first-line therapy, compared with sunitinib alone in patients with metastatic
and/ or locally advanced RCC. Following a planned interim analysis, the independent Data
Safety Monitoring Board (DSMB) has recommended that the trial continues until completion.
Final data from the study are expected in 2015. IMA901 is a rationally designed cancer
vaccine comprising 10 different tumor-associated peptides (TUMAPs) that are found to be
highly over-expressed in the majority of patients suffering from RCC.
The fundraising will also allow immatics to invest in its unique XPRESIDENT(R)
platform to extend its “Human Immunopeptidome Program” which is focused on identifying
hundreds of novel, high quality targets for the most common cancer indications. As part of
this program, immatics will also use XPRESIDENT(R) to screen the immunopeptidome of
relevant healthy tissue to ensure the selectivity of its novel targets based on their
exclusive or strong over-presentation in tumors vs. healthy tissues. The program will also
further strengthen the Company’s IP position around all highly over-presented TUMAPs given
their value as targets for a range of immunotherapy approaches including cancer vaccines,
adoptive cellular therapy and antibodies/soluble T-cell receptors that promise important
advances in the treatment of virtually every type of cancer.
1. The Immunopeptidome constitutes the entity of peptides presented by HLA receptors
on the surface of cells including tumor cells and is the most relevant information to help
T cells to differentiate between healthy and diseased cells.
Paul Higham, CEO of immatics, said: “The completion of our Series D fundraising
demonstrates the continued commitment to the Company’s strategy to generate value from our
TUMAP-based approach to cancer immunotherapy. The independent DSMB’s recommendation means
that we will work to complete our phase 3 trial with IMA901 in patients with renal cell
carcinoma and we remain on track to announce the final results of this study in 2015. In
addition, by investing in our Human Immunopeptidome Program we intend to extend our global
leadership in the discovery of tumor-associated peptides. We expect these specific, high
quality targets to play a crucial role in delivering the significant promise of cancer
immunotherapy as they act as a very specific ‘navigation system’ for the body’s T cells,
allowing them to be used to treat a wide range of cancers.”
immatics biotechnologies GmbH is a clinical-stage biopharmaceutical company leading
the development of advanced immunotherapies that are active against cancer. immatics’ lead
product, IMA901, is in a pivotal phase 3 study after completing a successful randomised
phase 2 trial in renal cell carcinoma. immatics’ pipeline also includes IMA910, which has
reported encouraging overall survival data in patients with advanced colorectal cancer,
and IMA950, which has completed a phase 1 study in patients with glioma. immatics’
vaccines contain multiple tumor-associated peptides (TUMAPs) to maximize the chances of
clinical success by increasing the number of targets on cancer cells that they address and
are ‘drug-like’, i.e., fully synthetic, off-the-shelf, easily scalable, and stable.
immatics’ unique and world-leading technology platform XPRESIDENT(R) discovers novel
relevant cancer antigens known to be expressed on tumor cells. These TUMAPs constitute the
basis for developing therapeutic cancer vaccines and other immunotherapies including
peptide-targeting compounds such as antibodies, soluble T-cell receptors and adoptive
cellular therapies. In contrast to widely used existing in silico and indirect methods to
identify peptide antigens, immatics’ TUMAPs are confirmed to be naturally expressed in
primary cancer tissue.
immatics signed a cancer immunotherapy collaboration with Roche in November 2013 to
research, develop and commercialize a number of new TUMAP-based cancer vaccine candidates
and other immunotherapies, targeting primarily gastric, prostate and non-small cell lung
immatics is based in Tuebingen and Martinsried (Munich), Germany, and employs approx.
80 people (FTEs).
For additional information on immatics please visit http://www.immatics.com or
Paul Higham, CEO Dr. Nikola Wiegeler, Assistant to the Management immatics biotechnologies GmbH Phone: +49-7071-5397-110 E-mail: email@example.com Citigate Dewe Rogerson David Dible / Chris Gardner / Sita Shah Phone: +44-207-638-9571 E-mail: firstname.lastname@example.org